China’s fifth new corona vaccine enters phase III clinical trials to be conducted in Uzbekistan-IT & Health

According to news from the English version of Xinhuanet on November 14, the government of Uzbekistan recently told the media that the new corona vaccine developed by Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. (hereinafter “Zhifeilongkoma”) is will launch in Uzbekistan. Clinical trials. This is the fifth vaccine candidate from China to enter phase III clinical trials.

Screenshot of the English version of Xinhuanet. The news also indicated that the vaccine has been delivered to Uzbekistan and that several Chinese experts have also been installed, who will be responsible for monitoring volunteers and training Uzbek doctors.

According to the official account of the Chinese news agency “New Silk Road Observation” on October 30, an expert from the Uzbekistan Epidemic Prevention and Control Headquarters said: “If the volunteers have any complications or adverse reactions, they will be treated for free. In addition, the volunteers for the vaccination of the new crown can also receive the corresponding subsidies. ” Earlier, Uzbekistan’s Minister of Innovation and Development, Ibrahim Abdurakhmonov, said in an interview with Uzbekistan TV Channel 24: The safety of China’s new corona vaccine is much higher than that of other similar vaccines.

According to a Reuters report on November 11 Eastern Standard Time, Uzbekistan has stated that it is also negotiating with the Sinopharm Group and the pharmaceutical manufacturers of the Russian “Satellite V” vaccine on possible trials. More than 69,000 people have been diagnosed with the new crown in Uzbekistan, with 589 deaths and around 200 new cases in a single day. Uzbekistan has implemented a national blockade twice, but there are no plans to block it again. Uzbek President Mirziyoyev has instructed officials to learn how to live and work in a pandemic.

The vaccine, which will enter phase III clinical trials, was jointly developed by the Institute of Microbiology, the Chinese Academy of Sciences and Zhifeilongkoma.

According to the earlier announcement by the Institute of Microbiology of the Chinese Academy of Sciences, on June 19, the vaccine was officially approved by the National Administration of Medical Products for clinical drug trials and clinical trials were started. Recruitment of healthy adults ages 18 to 59 in Beijing, Chongqing and Hunan Province began on June 23. Phase I clinical trials began at Chongqing Medical University Second Affiliated Hospital and Beijing Chaoyang Hospital. The Clinic II launched on July 10 Periodic Test. On October 22, the unmasking meeting of the phase I / II clinical trial of vaccines was held. The unmasking results were in line with expectations. The new recombinant coronavirus subunit vaccine has good safety and immunogenicity in the population that complies with the clinical trial protocol. Please continue with the next clinical trial.

Genetically engineered recombinant subunit vaccines, also known as recombinant protein vaccines. Regarding the technical characteristics of the vaccine developed in cooperation with Zhifeilongkoma, the Institute of Microbiology of the Chinese Academy of Sciences once introduced that the recombinant protein vaccine is the expression and purification of pathogenic antigen proteins in genetically engineered cells. , and then the vaccine is prepared. The antigen in this new coronavirus vaccine developed by Gaofu’s team from the Institute of Microbiology and Yan Jinghua’s team is a protein S receptor domain (RBD) dimer antigen based on a structural design. It has a unique structure and does not carry any kind of strange labels. Have independent intellectual property rights. The hACE2 transgenic mouse challenge experiment demonstrated that the vaccine has an obvious protective effect. The results of the challenge and protection tests of the Rhesus monkey show that the immunity of the vaccine can induce high levels of neutralizing antibodies, significantly reduce the viral load of lung tissue, reduce the lung damage caused by virus infection and have protective effects obvious. The vaccine is produced industrially through modified cell strains, with high productivity, low cost and strong accessibility.

This vaccine is a key special project of the National Plan for Special Emergency R + D + i “Prevention and Control of Public Safety Risks and Technology and Emergency Equipment” (Project Number: 2020YFC0842300). The technical route is the “reorganization” in the “5 routes” of the new corona vaccine deployed by the Ministry of Science and Technology Subunit vaccine “.

This recombinant subunit vaccine is China’s fifth vaccine to enter Phase III clinical trials. The four above vaccines entered Phase III clinical trials using two technical routes, inactivated vaccines and adenovirus vector vaccines. The four vaccines are two inactivated vaccines developed by Sinopharm Group, an inactivated vaccine developed by Kexing Zhongwei, and an adenovirus vector vaccine developed by Academician Chen Wei’s team.

On October 20, Zheng Zhongwei, leader of the vaccine research team of the Research Team of the Joint Prevention and Control Mechanism of the State Council and director of the Center for the Development of Medical Science and Technology of the National Health and Health Commission, once said at the press conference that the first four vaccines that entered the phase III clinical trial phase were generally progressing smoothly. So far, a total of approximately 60,000 subjects have been vaccinated and no reactions have been reported. serious adverse events, which initially shows good safety.